Evidence map›Paper›PMID 38707351›Full record

ArticleHeliyon2024

Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experience.

Alexandra Lebedeva, Olesya Kuznetsova, Maxim Ivanov, Alexandra Kavun, Egor Veselovsky, Ekaterina Belova, Vladislav Mileyko, Valentina Yakushina, Polina Shilo, Alexey Tryakin and 4 more

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alexandra LebedevaOncoAtlas LLC, 119049, Moscow, Russian Federation.
Olesya KuznetsovaN.N. Blokhin Russian Cancer Research Center, 119049, Moscow, Russian Federation.
Maxim IvanovOncoAtlas LLC, 119049, Moscow, Russian Federation.
Alexandra KavunOncoAtlas LLC, 119049, Moscow, Russian Federation.
Egor VeselovskyOncoAtlas LLC, 119049, Moscow, Russian Federation.
Ekaterina BelovaOncoAtlas LLC, 119049, Moscow, Russian Federation.
Vladislav MileykoOncoAtlas LLC, 119049, Moscow, Russian Federation.
Valentina YakushinaOncoAtlas LLC, 119049, Moscow, Russian Federation.
Polina ShiloLahta Clinic Medical Center, 197183, St.Petersburg, Russian Federation.
Alexey TryakinN.N. Blokhin Russian Cancer Research Center, 119049, Moscow, Russian Federation.
Alexey RumyantsevN.N. Blokhin Russian Cancer Research Center, 119049, Moscow, Russian Federation.
Fedor MoiseenkoState Budgetary Healthcare Institution «Saint-Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care (oncological)», 197758, Saint-Petersburg, Russian Federation.
Mikhail FedyaninN.N. Blokhin Russian Cancer Research Center, 119049, Moscow, Russian Federation.
Dmitry NosovThe Central Clinical Hospital of the Administrative Directorate of the President of the Russian Federation, 121359, Moscow, Russian Federation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genomic profiling, or molecular profiling of the tumor, is becoming a key component of therapeutic decision making in clinical oncology, and is typically carried out via next generation sequencing. However, the interpretation of the results and evaluation of rationale for targeting the uncovered alterations is challenging and requires a deep understanding of cancer biology, genetics, genomics and oncology. Multidisciplinary molecular tumor boards represent a promising strategy in the facilitation of molecularly-informed therapeutic decisions, and usually consist of specialists with various fields of expertise. To effectively communicate the biological and clinical significance of genomic findings, as well as to make molecular tumor board discussions more productive, we developed and implemented evidence blocks into case discussions in our center. We found that this approach facilitated clinicians' understanding of the results of genomic profiling, and resulted in shorter yet more efficient case discussions within the molecular tumor board. Here, we discuss our experience with evidence blocks and how their implementation influenced the molecular tumor board practice.

Identifiers

PMID38707351
PMCPMC11068803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.